ClinicalTrials.gg
RecruitingNCT06899997OBESIMMUpdated Apr 23, 2026

Study of the Effects of Time-Restricted Feeding on the Immune Function of Individuals With Obesity

An interventional study of Time-restrictred feeding and Non-time restricted feeding in Obesity and Obesity-related Medical Conditions, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 2 sites in France. Open to female participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris — 16 open to participants now, 16 under way, 1 of them phase 3. Obesity · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
35th of 38
24 · median 110
Started
2025
with 5 others
No phase
30 of 58
9 open now
Primary completion
2027-09
later than 8 of 15 live
Registered
54th of 58
by date

Among the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, this one is the 35th largest by planned enrollment of the 38 interventional ones that give a count, is one of 6 that started in 2025, is one of 30 with no phase, reaches primary completion later than 8 of the 15 other live ones, and was the 54th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

16 of the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 64 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The goal of this randomized trial is to: 1) investigate the immunological landscape of patients with obesity and conduct an in-depth functional characterization of their immune system; and 2) precisely define the effects of time-restricted feeding (TRF) on immune function in patients with obesity; 3) uncover the underlying mechanisms by which TRF modulates the immune system patients with obesity through a multi-omics approach.

The main questions it aims to answer are: i) what is the underlying cause of impaired immunocompetence in patients with obesity? ii) how nutritional interventions improve the immune function of patients with obesity? Patients with obesity following TRF (8 h eating window ranging from 6-8 am to 14-16 pm) will be compared to patients with obesity without TRF control schedule (14h eating window ranging from 6-8 am to 8-10 pm). In addition to patients with obesity, the present study aims to recruit a group of a reference healthy group (BMI between 18.5-24.9 kg/m²) that will not receive any nutritional intervention.

The following endpoints will be collected: Body weight and composition using Bioelectrical Impedance Analysis, resting energy expenditure (REE) using indirect calorimetry, blood glucose levels using a continuous glucose monitoring (CGM) device, metabolic parameters (fasting blood glucose levels, C-peptide, HbA1c, insulin, HOMA-IR, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, hepatic enzymes), and cytokine profile.

Blood and stool, samples will be collected to establish metagenomic, transcriptomic, cytomic and metabolomic analyses.

03

Conditions studied

  • Obesity and Obesity-related Medical Conditions

Browse trials for

Keywords

  • Obesity
  • Immune system
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with obesity

  • Women
  • Age 18-64 years
  • between 40-50 kg/m²
  • Self-reported eating pattern window of more than 14h
  • Three meal eating pattern
  • Stable body weight (less than 10% of current body weight during the last 3 months)
  • Social security affiliation
  • Written consent
  • Good understanding of the French language

Lean patients

  • Women
  • Age 18-64 years
  • Body mass Index between 18.5-24.9 kg/m²
  • Self-reported eating pattern window of more than 14h
  • Social security affiliation
  • Written consent
  • Good understanding of the French language

Exclusion criteria

Exclusion Criteria:

  • Diabetes type I or II
  • Major cardiovascular disease
  • Pregnancy
  • Medication that could affect the study outcomes (i.e. anti-inflammatory drugs, antibiotics, immunosuppressors)
  • Use products intended for weight loss
  • Night work shift
  • Past record of malignant tumors
  • Serious liver dysfunction or chronic kidney disease
  • Eating disorders
  • Chronic viral disease ( or C, ) or inflammatory systemic diseases (i.e. Crohn's disease, rheumatoid arthritis)
  • Serious cardiovascular or cerebrovascular disease within 6 months before randomization
  • Severe gastrointestinal diseases or gastrointestinal surgery in the 12 months before randomization
  • Under guardianship, curatorship, deprived of liberty
  • Unable or unwilling to sign the form.
  • Patient on AME (state medical aid)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Time-restricted feeding

    Women with grade 3 obesity (BMI 40-50 kg/m²) follow a time-restricted feeding (TRF) pattern consisting of an 8 h eating window (from 6-8 am to 14-16 pm) followed by a 16 h fasting period.

    Other: Time-restrictred feeding

  • Experimental
    Non-Time restricted feeding

    Women with grade 3 obesity (BMI 40-50 kg/m²) follow a 14h eating window (from 6-8 am to 8-10 pm), followed by a 10 h fasting period.

    Other: Non-time restricted feeding

  • No intervention
    Control

    Women with a healthy body weight without any dietary intervention

Interventions

  • OtherTime-restrictred feeding

    Time-restricted feeding pattern consisting of an 8 h eating window (from 6-8 am to 14-16 pm) followed by a 16 h fasting period

  • OtherNon-time restricted feeding

    14h eating window (from 6-8 am to 8-10 pm), followed by a 10 h fasting period

06

What researchers measure

Primary outcomes

  1. Level of inflammatory cytokine IL-1β

    The mean difference in inflammatory cytokine IL-1β in patients with obesity after 10 weeks under TRF versus patients with obesity without TRF.

    Time frame: 10 weeks

Secondary outcomes

  1. Percent of weight change from baseline

    Time frame: Baseline, Week 10

  2. Change in lean mass (expressed in kg), measured using Bioelectrical Impedance Analysis from baseline

    Time frame: Baseline, Week 10

  3. Change in fat mass (expressed in kg), measured using Bioelectrical Impedance Analysis from baseline

    Time frame: Baseline, Week 10

  4. Change in resting energy expenditure (kcal/day), measured using indirect calorimetry, from baseline

    Time frame: Baseline, 10 weeks

  5. Change in fasting blood glucose levels from baseline

    Time frame: Baseline, 10 weeks

  6. Change in fasting C-peptide levels from baseline

    Time frame: Baseline, 10 weeks

  7. Change in HbA1c Levels from Baseline (Percentage Points)

    Time frame: Baseline, 10 weeks

  8. Change in fasting insulin levels from baseline

    Time frame: Baseline, 10 weeks

  9. Change in HOMA-IR from baseline

    Time frame: Baseline, 10 weeks

  10. Change in lipid profile from baseline

    Time frame: Baseline, 10 weeks

  11. Change in ALT and AST levels (U/L) from baseline

    Time frame: Baseline, 10 weeks

  12. Change in Plasma Cytokine Levels from Baseline Using Luminex Assay

    Time frame: Baseline, 10 weeks

  13. Changes in blood metabolome evaluated by gas chromatography and liquid chromatography coupled with high-resolution mass spectrometry

    Time frame: Baseline, 10 weeks

  14. Changes in gut microbiome diversity using shotgun metagenomics

    Time frame: Baseline, 10 weeks

  15. Changes in gene expression profile assessed by RNA sequencing

    Time frame: Baseline, 10 weeks

  16. Changes in blood immune cell populations measured using spectral flow cytometry

    Time frame: Baseline, 10 weeks

07

Study locations

1 of 2 sites recruiting
  • HEGP - digestive surgery
    Paris, 75015, France
    Active, not recruiting

    Not enrolling at this site.

  • HEGP - nutrition department
    Paris, 75015, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared

Supporting information: Study protocol, Informed consent form

Time frame: Two years after the last publication

Access criteria: Data sharing must be accepted by the sponsor and the PI based on a scientific project and scientific involvement of the PI team. Collaboration will be fostered. The founder could be involved in the decision. Teams wishing obtain IPD must meet the sponsor and IP team to present scientifics (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractualization. Processing of shared data must comply with European General Data Protection Regulation (GDPR).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Sep 2027, 22 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 22 months is close to that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2025
First posted
Mar 28, 2025
StartActual
Nov 3, 2025
Primary completionEst.
Sep 15, 2027
CompletionEst.
Sep 15, 2027
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06899997
Collaborators
National Research Agency, France
Responsible party
Sponsor
First posted
Mar 28, 2025
Start date
Nov 3, 2025
Primary completion
Sep 15, 2027 (estimated)
Completion
Sep 15, 2027 (estimated)
Last update
Apr 23, 2026

Study contacts

Cléo BOURGEOIS
Contact
cleo.bourgeois@aphp.fr
0156095638 ext. +33
Sébastien CZERNICHOW, MD
Contact
sebastien.czernichow@aphp.fr
0156093067 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion